Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Dec 2018

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Autoimmune haemolytic anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Rigel Pharmaceuticals
  • Most Recent Events

    • 03 Dec 2018 Status changed from planning to not yet recruiting.
    • 06 Nov 2018 According to a Rigel Pharmaceuticals media release, Phase 3 trial design for fostamatinib in autoimmune hemolytic anemia (AIHA) to be submitted to U.S. Food and Drug Administration (FDA) in early November.This trial is anticipated to begin in first half of 2019.
    • 05 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top